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INTRODUCTION
Rheumatoid Arthritis (RA) is an immune disease that can have detrimental consequences if left untreated. Apart from joint destruction with subsequent disability, RA patients also suffer from various comorbidities, resulting in increased mortality rate.
1,2 Joint destruction may already occur early in the disease course. 3 Early and aggressive treatment can be highly effective in controlling inflammatory activity and development of erosions [4] [5] [6] Some studies even suggest that treatment within this early 'window of opportunity' might alter the natural history of RA. 7, 8 Early recognition of RA is thus highly important and several models have been created that predict the development of (erosive) RA in patients with undifferentiated arthritis. 9, 10 Recently, the classification criteria for RA itself have been renewed to enable earlier classification. 11 However, these models and the new criteria concern patients that already have arthritis. To date no model exists to predict the development of RA before arthritis is clinically apparent.
Patients presenting with arthralgia and a positive test for anti-cyclic citrullinated peptide antibodies (aCCP) and/or IgM rheumatoid factor (IgM-RF) (seropositive) are at risk for developing RA. 12 However, since not all of these patients develop arthritis 12 the question remains which of these patients will do so and within which time frame. We prospectively followed a cohort of seropositive arthralgia patients and made an easily applicable prediction rule consisting of nine clinical variables for the development of arthritis in these patients.
PATIENTS AND METHODS

Study population
Between August 2004 and June 2011, patients with a positive aCCP and/or IgM-RF status and (a history of) arthralgia, but not arthritis were recruited at rheumatology outpatient clinics in the Amsterdam area of the Netherlands. 12 Absence of arthritis was confirmed by physical examination of 44 joints by a trained medical doctor (WB or LAS) and a senior rheumatologist (DS). 13 Patients with arthritis as revealed by chart review or baseline physical examination, a negative aCCP and IgM-RF status on second analysis, age >70 years, previous treatment with a disease modifying antirheumatic drug (DMARD) or recent glucocorticoid treatment (<3 months) were excluded. Patients without follow-up due to loss or recent inclusion (follow-up less than 6 months) were excluded. Figure 1 is a flowchart of inclusion. In total, 374 seropositive arthralgia patients were analyzed. Of these patients, 83 were also included in a randomized placebo-controlled trial studying the effects of two intramuscular dexamethasone injections on arthritis development. Since dexamethasone did not delay or prevent arthritis these patients were considered suitable for the present analysis. At baseline, medical history, details of joint complaints and the number of tender joints at physical examination were recorded. 15 Patients were seen semiannually the first year and annually thereafter. Extra visits were planned if arthritis developed.
Development of arthritis in any of 44 joints was independently confirmed by two investigators (WB or LAS and DS). 13 Median follow-up was 32 months (inter quartile range (IQR): 13-48 months).
This study was approved by the local ethics committee and all participants gave informed consent.
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Laboratory investigations aCCP and IgM-RF levels were determined at baseline by second-generation aCCP ELISA (Axis Shield, Dundee, UK) and inhouse ELISA, respectively, as described previously. 16 The cut-off level for aCCP positivity was set at five arbitrary units/ml (AU/ml), according to the manufacturer's instructions. The cut-off level for IgM-RF positivity was set at 30 IU/ml determined on the basis of the analysis of receiver operating characteristic (ROC) curves. 16 C reactive protein (hsCRP) was measured using a highly sensitive latex-enhanced assay on a Hitachi 911 analyzer (Roche Diagnostics) and the cut-off level for CRP positivity was set at 10 mg/l, according to the manufacturer's instructions. HLA genotyping: HLA-DQ typing was performed as described previously. 17 Results of the pooled analysis are reported. Cases were treated as censored after the date of their last visit. Continuous variables with a non-linear association with the outcome variable were categorized using clinically applicable cut offs or percentiles. Categories were pooled if corresponding regression coefficients were similar. IgM-RF and aCCP status and titres were combined into one variable with four categories based on previous research ( Table 1) . 12 In the multivariate analysis all variables were entered in the model and subsequently selected with a backward stepwise procedure (p removal 0.1). Nagelkerke's R 2 was used to calculate the proportion of explained variation by this model.
A simplified prediction rule was obtained by rounding the regression coefficients to half points, which were then multiplied by 2 for easier clinical applicability. The diagnostic performance of the prediction model and rule were evaluated using the area under the curve (AUC) of receiver operating characteristic (ROC) curves and
Harrell's C in the original dataset. ROC analysis was performed for arthritis at one, three and at five years. Patients with less than one, three or five years of follow-up, respectively, were treated as missing in the ROC analyses. Harrell's C is a performance measure that also takes into account time until development of arthritis, estimating the probability of concordance between the predicted and observed responses. 19 Values around 0.5 indicate no predictive discrimination, values close to 1, high predictive discrimination.
For internal validation, cross validation was performed, in which 300 randomly drawn cases from each imputation set were used as the test sets to create the prediction model with Cox regression, using the pooled analysis over the 5 datasets. The remaining 74 cases were subsequently used as the validation set to calculate the AUC of the ROC curves and Harrell's C as described above. This procedure was repeated 1000 times. The average scores from these 1000 analysis for the resulting regression coefficients, AUC and Harrell's C are presented.
RESULTS
Arthritis development
In total 374 patients, 76% female, mean ±SD age 49 ±11, were included in the 
Univariate analysis
To study which baseline characteristics could predict arthritis development, univariate Cox regression was performed first. Patients that developed arthritis versus those that did not develop arthritis were more often non-alcohol drinkers, used NSAIDs more often, more often had symptoms less than 12 months, intermittent symptoms, symptoms in both upper and lower extremities, a visual analogue scale (VAS) pain ≥50, morning stiffness ≥1 hour and reported swollen joints, had a higher mean tender joint count, and were more often aCCP and SE positive ( Table 1) .
Multivariate analysis
Performance measures of this model were slightly lower than of the full model (Table 3 ) and Nagelkerke's R 2 was 0.29. 
Prediction of arthritis.
For each patient a risk score was calculated by multiplying each variable with the regression coefficient of the prediction model. To create a more easily applicable prediction rule, regression coefficients were rounded to half points and multiplied by 2 (table 2 and Using Cox regression with the calculated risk score of the prediction rule as independent variable, the HR (95% CI) of the prediction rule per risk point was 1.58
(1.46-1.72). In figure 2D , the arthritis free survival curves are shown for all patients receiving a score from 1 to 11 -the one patient receiving 12 points was censored after 6 months and is not shown. As is clear from the survival curves, patients could be categorized into three risk groups: patients receiving 0 to 4 points having a low risk, patients receiving 5 to 6 points having intermediate risk Figure 2E depicts the arthritis free survival curves per risk group. After one year, 3% of the low risk group developed arthritis, 16% of the intermediate group developed arthritis, and 43% of the high risk group developed arthritis. After three years, these percentages were 7%, 36% and 74%, respectively.
After five years these percentages were 12%, 43% and 81%, respectively ( Figure 2E ). For clinical applicability, a concern might be that in this study we chose the development of arthritis as outcome. However, arthritis can be self-limiting and still might not need DMARD treatment. We therefore also took the 2010 and 1987 RA criteria into account as outcome variables. The prediction rule then still had good discriminative abilities, although the proportion of explained variance of the prediction model for the 1987 RA criteria was low. An alternative outcome measurement would be erosive arthritis. However, in the present cohort, follow-up data during the arthritis phase on radiographic progression is still too little to
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provide reliable results. Therefore we did not take erosive arthritis into account as outcome variable, although it will be interesting to explore the discriminative ability of this prediction rule for erosive arthritis in future studies.
Another concern is that, while the prediction rule could discriminate high risk patients very well from low risk patients, there was still a group of patients with intermediate risk comprising 27% of the cohort. These patients had a risk of approximately 40% to develop arthritis within 5 years, which is considerable, but also still fairly uncertain. In such a patient group it might be useful to do additional tests such as genetics, RNA profiling, antibody profiling or other test methods that are currently being developed. Also, a more detailed study of the quality of the symptoms experienced by patients in this phase of the disease may be helpful. This has recently been identified as a research priority by the EULAR study group for risk factors for RA. 20 Additionally, different imaging techniques to assess the joints such as ultrasound, PET and MRI might prove to be useful in these patients. 21, 22 An interesting finding in this patient group was that alcohol consumption seems to protect against development of arthritis, as we and others have previously reported. [23] [24] [25] [26] Although we would not advise patients to consume large amounts of alcohol, alcohol intake seems beneficial and, as our analysis indicates, should be taken into account in considering the risk of arthritis.
Factors that were surprisingly lacking in the model were presence of an acute phase response, presence of the SE, and smoking. We have previously shown that CRP levels and sPLA2 levels rise prior to development of RA in comparison to healthy individuals, but stay within the normal range. 27, 28 In the present cohort, we have also observed that the CRP levels were slightly higher than in healthy blood donors but still within normal limits. Therefore, an elevated CRP level was not associated with arthritis development. 29 The presence of the SE on the other hand, was strongly associated with arthritis development in the univariate analysis. However, this association was not present in the multivariate analysis. An explanation for this phenomenon can be that the contribution of the SE to RA development is mediated via the presence and perhaps levels of ACPA. 30 The same could be true for smoking, which is highly associated with the formation of ACPA. The method of patient selection used for this study may cause the loss of association with arthritis of such risk factors within this cohort. We chose to develop a prediction rule for seropositive arthralgia patients from out of a clinical perspective and think the prediction rule will be a useful tool for this patient group. However, there are other groups of individuals at risk for development of arthritis who might be seronegative. Therefore, it is essential that the prediction rule that we developed is validated in other prospectively followed cohorts of patients at risk for the development of RA, such as first degree family members or patients with inflammatory type arthralgia. Such cohorts are currently being set up and followed and it will be exciting to see the results of these studies and the comparison with our cohort.
In conclusion, we developed a prediction rule for the development of arthritis in seropositive arthralgia patient that is discriminative and easily applicable. It is a first step towards better understanding of and care for this patient group.
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